ATE326700T1 - SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß - Google Patents

SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß

Info

Publication number
ATE326700T1
ATE326700T1 AT00965965T AT00965965T ATE326700T1 AT E326700 T1 ATE326700 T1 AT E326700T1 AT 00965965 T AT00965965 T AT 00965965T AT 00965965 T AT00965965 T AT 00965965T AT E326700 T1 ATE326700 T1 AT E326700T1
Authority
AT
Austria
Prior art keywords
phf
absence
decrease
inhibitors
assembly
Prior art date
Application number
AT00965965T
Other languages
English (en)
Inventor
Bergen Martin Von
Jacek Biernat
Eva-Maria Mandelkow
Eckhard Mandelkow
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE326700T1 publication Critical patent/ATE326700T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00965965T 1999-09-09 2000-09-11 SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß ATE326700T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99117805 1999-09-09

Publications (1)

Publication Number Publication Date
ATE326700T1 true ATE326700T1 (de) 2006-06-15

Family

ID=8238955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965965T ATE326700T1 (de) 1999-09-09 2000-09-11 SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß

Country Status (7)

Country Link
EP (1) EP1214598B1 (de)
JP (1) JP2003508788A (de)
AT (1) ATE326700T1 (de)
AU (1) AU7653100A (de)
CA (1) CA2384006A1 (de)
DE (1) DE60028055D1 (de)
WO (1) WO2001018546A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138072A1 (de) * 2001-08-03 2003-02-27 Fraunhofer Ges Forschung Verfahren und Vorrichtung zum Bestimmen von Proteinen auf einem Reaktionsträger
WO2004007547A2 (en) * 2002-07-12 2004-01-22 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Truncated tau proteins
EP1516930A1 (de) * 2003-09-16 2005-03-23 Georg-August Universität Göttingen Zelluläres Model der Tauopathien zur "Lead"-Identifikation und zur Entdeckung von Wirkstoffen
ES2264841B1 (es) * 2003-12-17 2008-01-01 Consejo Sup. Investig. Cientificas Procedimiento para la identificacion de compuestos inhibidores del proceso de ensamblaje de proteinas tau y sus aplicaciones.
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
JP5099675B2 (ja) * 2004-12-28 2012-12-19 学校法人東京理科大学 蛍光分子プローブを用いた新規薬剤スクリーニング方法
ES2321996B1 (es) * 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
ATE524487T1 (de) * 2007-01-11 2011-09-15 Univ Ramot Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen
US9518101B2 (en) 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
DE102012019882A1 (de) 2012-10-05 2014-04-10 Forschungszentrum Jülich GmbH Peptide zur Behandlung und Frühdiagnose von Morbus Alzheimer und anderer Tauopathien
WO2014066002A1 (en) * 2012-10-23 2014-05-01 The Johns Hopkins University Novel self-assembling drug amphiphiles and methods for synthesis and use
RU2730668C2 (ru) 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
US11906530B2 (en) 2016-12-30 2024-02-20 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Methods for the detection of tau protein aggregates
US10934332B2 (en) 2017-03-15 2021-03-02 The Regents Of The University Of California Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment
JP2020515846A (ja) * 2017-03-28 2020-05-28 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． タウタンパク質凝集を調節する化合物の検出のための方法
EP3784687A1 (de) * 2018-04-27 2021-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Verfahren zur herstellung von phfs-ähnlichen tau-aggregaten
KR20210125037A (ko) * 2019-02-08 2021-10-15 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
GB202010620D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd System
WO2023135201A1 (en) * 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein fragment in a sample

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
WO1999062548A1 (en) * 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies

Also Published As

Publication number Publication date
AU7653100A (en) 2001-04-10
WO2001018546A3 (en) 2001-09-27
EP1214598B1 (de) 2006-05-17
DE60028055D1 (de) 2006-06-22
EP1214598A2 (de) 2002-06-19
JP2003508788A (ja) 2003-03-04
CA2384006A1 (en) 2001-03-15
WO2001018546A2 (en) 2001-03-15
WO2001018546A9 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
ATE326700T1 (de) SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß
André et al. Proteomic analysis of the tetraspanin web using LC‐ESI‐MS/MS and MALDI‐FTICR‐MS
DE69934228T2 (de) Domäne 1 beta2-gpi polypetiden und deren diagnostische und therepeutische verwendungen
US4188264A (en) Process for determining bacterial endotoxin and reagents used therefor
WO1999006545A8 (en) Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
Pataridis et al. Identification of collagen types in tissues using HPLC‐MS/MS
NZ312840A (en) Ketoheterocyclic inhibitors of factor Xa
Kaidoh et al. Phylogeny of C4b-C3b cleaving activity: similar fragmentation patterns of human C4b and C3b produced by lower animals.
AU2003296085A1 (en) Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
Highashihara et al. Inhibition of conformational change in smooth muscle myosin by a monoclonal antibody against the 17-kDa light chain
ATE259505T1 (de) Test zur quantifizierung von arthritiszustanden
DE60016405D1 (de) Neurodegenerative-erkrankung verwandtes gen
AU5722499A (en) G protein-coupled receptor agonists or antagonists
WO1999054360A1 (en) Substance with antithrombotic activity and method for detecting glycokallidin
AU4136797A (en) Novel semaphorin gene: semaphorin y
Wieding et al. Determination of soluble fibrin: a comparison of four different methods
TW200700553A (en) Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
KR100788435B1 (ko) Ⅷ 안티팩터 동종항체
DE69130530D1 (de) Methode zur bildung eines aminosäurehydantoinderivats unter verwendung eines n-substituierten ketenimins als aktivator
ATE315234T1 (de) Ein-schritttest zum nachweis von antimikrobiellen rückständen in eiern
AU2001232321B2 (en) Dioxin derivatives and method of measurement therewith
WO1996000284A1 (de) Verfahren zur stabilisierung von hydrolyseempfindlichen molekülen oder molekülteilen
US6232089B1 (en) CD23 processing enzyme preparation
WO2001036635A3 (en) Neurite outgrowth-promoting factor homologue and nucleic acids encoding same
WO2003060118A1 (fr) Proteine fer-soufre, complexe proteine-fad, transporteur d'electrons, et procede de mesure de l'inhibition de l'activite de ferredoxine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties